Thomas Jean Jaquin

Title: Thomas Jean Jaquin: Innovator in Anti-Cancer Therapeutics

Introduction

Thomas Jean Jaquin is a notable inventor based in Freising, Germany. He has made significant contributions to the field of cancer treatment through his innovative research and development of therapeutic agents. His work focuses on creating solutions that target specific tumor cells, enhancing the efficacy of cancer therapies.

Latest Patents

Jaquin holds a patent for an "Anti-cancer fusion polypeptide." This invention provides a fusion polypeptide that is specific for both CD137 and HER2/neu. The fusion polypeptide is designed to direct CD137 clustering and activation to HER2/neu-positive tumor cells. This innovation has potential applications in pharmaceuticals, particularly as anti-cancer agents and immune modulators for treating or preventing various human diseases, including tumors. The patent also covers methods for producing the fusion polypeptide, as well as compositions that include it. Additionally, it relates to nucleic acid molecules encoding the fusion polypeptide and methods for generating these molecules.

Career Highlights

Jaquin is currently associated with Pieris Pharmaceuticals GmbH, where he continues to advance his research in the field of oncology. His work is characterized by a commitment to developing effective treatments that can significantly impact patient outcomes.

Collaborations

Some of his notable coworkers include Marlon Hinner and Christine Rothe, who contribute to the collaborative efforts in research and development at Pieris Pharmaceuticals GmbH.

Conclusion

Thomas Jean Jaquin's innovative work in developing anti-cancer therapeutics exemplifies the critical role of inventors in advancing medical science. His contributions are paving the way for new treatment options that could improve the lives of many patients facing cancer.